Genmab A/S Files 6-K for S-8 Registration Statements
Ticker: GNMSF · Form: 6-K · Filed: May 6, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, procedural, stock-compensation
TL;DR
Genmab filed a 6-K, mostly procedural stuff for stock plans. No major news.
AI Summary
Genmab A/S filed a Form 6-K on May 6, 2024, to incorporate by reference into its existing S-8 registration statements. These statements relate to the company's stock-based compensation plans, specifically referencing file numbers 333-232693, 333-253519, 333-262970, and 333-277273.
Why It Matters
This filing is procedural and relates to the company's ongoing stock compensation plans, ensuring compliance with SEC regulations for its registered securities.
Risk Assessment
Risk Level: low — The filing is a routine procedural update related to existing registration statements and does not contain new material financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose is to incorporate by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
What are the Form S-8 registration statements related to?
The Form S-8 registration statements are related to the company's stock-based compensation plans.
When was this Form 6-K filed?
This Form 6-K was filed on May 6, 2024.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive office is located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Does this filing indicate any new financial results or operational updates for Genmab A/S?
No, this filing is a procedural report to incorporate previous filings into registration statements and does not present new financial results or operational updates.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-05-06 10:43:18
Filing Documents
- tmb-20240506x6k.htm (6-K) — 19KB
- tmb-20240506xex99d1.htm (EX-99.1) — 65KB
- tmb-20240506xex99d1a.htm (EX-99.1(A)) — 9670KB
- tmb-20240506xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240506xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-006710.txt ( ) — 9768KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: May 6, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated May 6, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix Share buyback program – Specification for April 29 – May 3, 2024